Fractyl Health Raises $20.7M Through Stock Offering

Fractyl Health, Inc. ( (GUTS) ) just unveiled an announcement.

On August 6, 2025, Fractyl Health, Inc. entered into an underwriting agreement with Ladenburg Thalmann & Co. Inc. for an offering of 19,047,619 shares of common stock and associated warrants, raising approximately $20.7 million in net proceeds. The company plans to use these funds to support its pipeline programs and general corporate purposes, with potential additional proceeds from warrant exercises. The offering closed on August 7, 2025, and includes conditions for warrant exercises and stockholder approvals, impacting the company’s financial strategy and stakeholder engagement.

The most recent analyst rating on (GUTS) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Fractyl Health, Inc. stock, see the GUTS Stock Forecast page.

Spark’s Take on GUTS Stock

According to Spark, TipRanks’ AI Analyst, GUTS is a Neutral.

Fractyl Health’s overall stock score is primarily impacted by its precarious financial situation, characterized by high leverage, negative equity, and reliance on external financing. While there are positive developments in clinical trials and corporate events, these are overshadowed by the company’s financial instability and weak technical indicators. The stock remains a high-risk investment with potential upside if clinical advancements translate into commercial success.

To see Spark’s full report on GUTS stock, click here.

More about Fractyl Health, Inc.

Fractyl Health, Inc. operates in the healthcare industry, focusing on developing innovative medical therapies. The company is primarily involved in advancing its Revita and Rejuva pipeline programs, which aim to address metabolic diseases.

Average Trading Volume: 669,058

Technical Sentiment Signal: Buy

Current Market Cap: $91.59M

See more data about GUTS stock on TipRanks’ Stock Analysis page.